Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Clinical trial NCT02939820 · APPROVED_FOR_MARKETING

Trial details

NCT number: NCT02939820
Sponsor: Alnylam Pharmaceuticals
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS

TTR-mediated Amyloidosis Amyloidosis, Hereditary Amyloid Neuropathies, Familial Familial Amyloid Polyneuropathies Amyloid Neuropathies Amyloidosis, Hereditary, Transthyretin-Related

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.